Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2024 and Business Update Aug 27, 2024 08:00AM
Portage Biotech Reports Fiscal Year-Ended March 31, 2024 Financial Results and Business Update Aug 15, 2024 07:00AM
Portage Biotech (PRTG) Announces 1:20 Reverse Share Split Aug 13, 2024 07:01AM
Portage Biotech Announces 1-for-20 Reverse Stock Split Aug 13, 2024 07:00AM
Portage Biotech (PRTG) to Expand Evaluation of Strategic Alternatives Apr 12, 2024 08:01AM
View Older Stories

Apr 12, 2024 08:01AM Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives
Mar 26, 2024 08:01AM Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares
Feb 28, 2024 05:10PM Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update
Jan 4, 2024 08:01AM Portage Biotech (PRTG) to pause further drug development in the PORT-2 iNKT program
Jan 4, 2024 08:00AM Portage Biotech Reports Business and Strategic Update
Nov 28, 2023 04:01PM Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023, and Business Update
Nov 6, 2023 08:01AM Portage Biotech Presents Updates on its iNKT and Adenosine programs at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
Sep 20, 2023 08:00AM Portage Biotech to Participate in Panel Discussion at the Cantor Global Healthcare Conference
Sep 5, 2023 08:00AM Portage Biotech Announces Collaboration with Merck to Evaluate Two Next-Generation Adenosine Antagonists in Combination with KEYTRUDA® (Pembrolizumab) in Solid Tumors
Aug 30, 2023 08:00AM Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023 and Business Update
Jul 31, 2023 04:05PM Portage Biotech Reports Fiscal Year-Ended March 31, 2023 Financial Results and Business Update
Jun 26, 2023 08:00AM Portage Biotech Announces First Patient Dosed in Phase 1a Trial of PORT-6 in Select Solid Tumors
Jun 5, 2023 08:00AM Portage Biotech Reports Updated Interim Data for Lead iNKT Engager, PORT-2, in a Phase 1/2 Trial for the Treatment of Advanced Melanoma and Metastatic Non-Small Cell Lung Cancer at the 2023 American S
Jun 1, 2023 08:00AM Portage Biotech to Participate in Panel Discussion During the 2023 BIO International Conference
Apr 26, 2023 05:00PM Portage Biotech Announces Upcoming PORT-2 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Mar 7, 2023 08:00AM Portage Biotech to Present at Oppenheimer’s 33rd Annual Healthcare Conference
Mar 1, 2023 08:00AM Portage Biotech Announces Results for Fiscal Quarter Ended December 31, 2022
Feb 27, 2023 04:05PM Portage Biotech Hosting Key Opinion Leader Event on Targeting the Adenosine Pathway in Cancer
Feb 15, 2023 08:00AM Portage Biotech to Participate in Citi's 2023 Virtual Oncology Leadership Summit
Nov 29, 2022 04:43PM Portage Biotech Announces Results for Fiscal Quarter Ended September 30, 2022
Nov 10, 2022 09:00AM Portage Biotech Presents Updated Data on the Phase 1/2 Trial Evaluating PORT-2 at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
Nov 8, 2022 08:02AM Portage Biotech (PRTG) Announces Clinical Trial Collaboration Agreement with Merck (MRK)
Nov 8, 2022 08:00AM Portage Biotech Announces Clinical Trial Collaboration Agreement with Merck
Oct 3, 2022 01:01PM Pfizer Completes Acquisition of Biohaven Pharmaceuticals
Sep 14, 2022 08:40AM Portage Biotech (PRTG) Issues Research and Development Update
Sep 14, 2022 08:39AM Portage Biotech Provides Research and Development Update
Sep 8, 2022 08:00AM Portage Biotech to Present at Upcoming Investor Conferences
Aug 29, 2022 08:00AM Portage Biotech Announces Results for Fiscal Quarter Ended June 30, 2022
Aug 18, 2022 08:05AM Portage Biotech (PRTG) announces Dr. Ian Walters, CEO, will be appointed Chairman
Aug 18, 2022 08:00AM Portage Biotech Announces Leadership Updates
Aug 1, 2022 09:10AM UPDATE -- Portage Biotech Announces Results for Fiscal Year Ended March 31, 2022
Aug 1, 2022 08:00AM Portage Biotech Announces Results for Fiscal Year Ended March 31, 2022
Jul 20, 2022 09:03AM Portage Biotech (PRTG) Acquires Remaining 22% Stake in Invariant Natural Killer T cell (iNKT) Agonist Platform
Jul 20, 2022 09:00AM Portage Biotech Acquires Outstanding Minority Interest of Invariant Natural Killer T cell (iNKT) Agonist Platform
Jul 6, 2022 04:05PM Portage Biotech Bolsters Pipeline with Acquisition of Four Candidates Targeting the Adenosine Pathway
Jul 6, 2022 01:00PM Global Coalition for Adaptive Research, Biohaven, and Vigeo Announce Commencement of Biohaven’s Troriluzole and Vigeo’S VT1021 in GBM AGILE Trial
Jun 6, 2022 08:00AM Portage Biotech Summarizes Data Presented at ASCO 2022 Annual Meeting Including Updates from Ongoing PORT-2 Study
May 10, 2022 06:45AM Pfizer to Acquire Biohaven Pharmaceuticals
Apr 27, 2022 06:45AM Pfizer (PFE) and Biohaven’s (BHVN) VYDURA Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine
Apr 27, 2022 06:45AM Pfizer and Biohaven’s VYDURA® (Rimegepant) Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine
Apr 25, 2022 08:05AM Portage Biotech (PRTG) Enters Cooperative Research and Development Agreement with U.S. National Cancer Institute and Stimunity
Apr 25, 2022 08:00AM Portage Biotech Enters Cooperative Research and Development Agreement with U.S. National Cancer Institute and Stimunity
Apr 13, 2022 10:00AM Portage Biotech Highlights Promising Data Presented on STING-Activating Therapy, PORT-5 (STI-001) at AACR 2022 Annual Meeting
Mar 31, 2022 08:00AM Portage Biotech Provides Update on Clinical-Stage and Development Programs
Mar 9, 2022 09:00AM Portage Biotech Announces Presentation of PORT-5 (STI-001) Late-Breaking Data at AACR 2022 Annual Meeting
Feb 25, 2022 07:00AM Biohaven Pharma (BHVN) Pfizer (PFE) Receive Positive CHMP Opinion for Migraine Treatment
Feb 25, 2022 06:59AM Biohaven and Pfizer Receive Positive CHMP Opinion for Migraine Treatment
Feb 24, 2022 05:43PM Portage Biotech Announces Financial Results and Provides Business Update for Third Quarter of 2022 Fiscal Year
Feb 15, 2022 08:00AM Portage Biotech Announces New Appointments to its Management Team and Board of Directors
Feb 14, 2022 07:01AM Biohaven Pharma (BHVN), Pfizer (PFE) Announce Positive Topline Results of Pivotal Trial of Rimegepant for the Acute Treatment of Migraine in China and South Korea
View Older Stories